BioNanoNet is contributing to several working groups that are part of the Austrian Cluster Platform and brings its scientifically based know-how into this platform.
You may find an article about the 5th Austrian Cluster Conference of the National Cluster Platform Austria in our BioNanoNet newsletter 04/2014 on page 23.
BioNanoNet supports the Austrian research community by participating in the national working group and shaping the call topics for European Calls.
The Austrian Nano Information Commission (NIK) is a formal collaboration of stakeholders working in nanotechnology that provides a structured process of communication among experts. It allows them to merge communications in a transparent matter and functions as a contact point for policy makers in order to provide information for courses of action.
In order to hold an unprejudiced discussion about the possible social opportunities and risks of nanotechnologies with respect to their consumer applications, early and open communication is critical. Therefore, the NIK acts as a guide for policy makers and public authorities and allows them to provide advice on nanotechnological issues in Austria. The first course of action was the formal inauguration of the head and members of the NIK by the director of the Federal Ministry of Health, Mr. Alois Stöger, on November 13, 2013, in Vienna. For more details, please see our BioNanonet Newsletter 04/2013 (page 25).
BioNanoNet is permanent member of the NanoInformationsKommission-Plenum group.
BioNanoNet is member of the Management Committee in COST-Action CA15107 MULTICOMP.
MC-Member: Christa Schimpel
MC-Substitute: Susanne Resch
WG3: Characterization, Health, Safety and Environment (HSE)
BioNanoNet is member of the Management Committee in COST-Action TD1402 RADIOMAG.
MC-Member: Christa Schimpel
COST Action CA17140 is the first, pan-European interdisciplinary network of representatives from academic institutions and small and medium enterprises including clinical research organizations (CROs) devoted to the development of nanosystems carrying anticancer drugs from their initial design, pre-clinical testing of efficacy, pharmacokinetics and toxicity to the preparation of detailed protocols needed for the first phase of their clinical studies.
By promoting scientific exchanges, technological implementation and innovative solutions, the Action will provide a timely instrument to rationalize and focus research efforts at the EU level in dealing with the grand challenge of nanomedicine translation in cancer, one of the major and societal-burdening human pathologies.
BioNanoNet is member of the Management Committee in COST-Action CA17140 Nano2Clinic.
MC-Member: Andreas Falk
MC-Substitute: Susanne Resch
BioNanoNet is member of the Management Committee in COST-Action MP1404 SimInhale
MC-Member: Eleonore Fröhlich
MC-Substitute: Christa Schimpel
WG4: Advanced imaging, patient monitoring and delivery verification
WG5: Toxicity, xenobiotics, risk assessment and policy development
BioNanoNet is member of the Management Committee in COST-Action CM1403 UPCON.
MC-Member: Andreas Falk
MC-Substitute: Christa Schimpel
http://www.cost.eu/COST_Actions/cmst/CM1403
Download final COST Action CM1403 Report
The European Society for Nanomedicine is a society of individuals and bodies across Europe that focuses on the clinical application of nanomedicine and its implications for individuals and society. Through this focus, it complements a number of already existing European platforms, initiatives, and framework-programmes that see their main task in linking researchers and industry.
The ETPN is an important European Technology Platform that contributes to the advancement nanomedicine in Europe.
BioNanoNet is member of the Executive Board of the ETPN and chair of the working group on safety and characterisation in nanomedicine (former WG toxicology and characterisation).
BioNanoNet is coordinator of the Austrian national technology platform NanoMedicine-Austria. Further information: https://www.bionanonet.at/testseite/national-technology-platforms/nanomedicine-austria
BioNanoNet is member of ETPIS.
More information about ETPIS: www.industrialsafety-tp.org/
BioNanoNet is member of the General Board of the NANOfutures a.s.b.l. and is a member of several working groups that are part of this network, active world-wide.
All Nanosafety-relevant European projects are connected to each other in the NanoSafetyCluster (NSC).
BioNanoNet is member of the Coordination Team.
The coordination team consist of Eva Valsami-Jones (University of Birmingham, UK; coordinator), Iseult Lynch (University of Birmingham, UK), Andreas Falk (BioNanoNet BioNanoNet Forschungsgesellschaft, Graz) and Flemming Cassee (National Institute for Public Health and the Environment RIVM, Bilthoven, Netherlands). The team will get secretarial support via H2020 project ACEnano for the coming years.
The role of the Coordination team is to:
BioNanoNet Forschungsgesellschaft mbH
Steyrergasse 17
8010 Graz, Austria
Tel.: +43 699 155 266 10
Legal Notice | mail